Polpharma Group

What Polpharma Group does

Polpharma Group is a privately held, vertically integrated pharmaceutical company headquartered in Amsterdam, Netherlands, with its principal operating entity Pharmaceutical Works Polpharma S.A. (Zakłady Farmaceutyczne Polpharma S.A.) based in Starogard Gdański, Poland. Founded in 1935, the company develops, manufactures, and distributes generic prescription medicines, consumer healthcare products, biosimilars (through the Polpharma Biologics spin-off), active pharmaceutical ingredients (APIs), and offers CDMO services to pharmaceutical clients. The group operates eight manufacturing competence centers and five R&D centers across Poland, Kazakhstan, and Russia, producing 5.2 billion tablets, 700 million capsules, and 185 million ampoules annually with approximately 5,600 employees (including 91 R&D doctorate holders). Its 4,000+ SKU portfolio spans cardiology, pediatrics, and ophthalmology, with proprietary strengths in hard-to-make generics, long-acting injectables, preservative-free ophthalmic formulations, and innovative fixed-dose combinations.

Name

Polpharma Group

Legal name

Polpharma Group B.V.

Website

https://polpharmagroup.com

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Polpharma Group is a privately held, vertically integrated pharmaceutical company manufacturing generic medicines, OTC products, biosimilars, and APIs, and providing CDMO services across 40+ countries in CEE, CIS, and Central Asia, with EUR 1.3bn in annual revenue.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Contract manufacturing
• CDMO services
• Finished dosage forms

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceuticals Sales: Sale of prescription medicines (generics) and consumer healthcare (OTC) products across 40+ countries. Portfolio of 4,000+ SKUs including hard-to-make generics and novel combinations.
2. Active Pharmaceutical Ingredients (API): Production and sale of generic APIs to customers worldwide. Polpharma API serves 60+ countries with state-of-the-art documentation and competitiveness.
3. Contract Manufacturing (CDMO/CMO): Customized contract manufacturing services for finished dosage forms with full analytical support, regulatory documentation, and day-zero launch capabilities for partners.
4. In-licensing and Out-licensing: Business development through strategic partnerships for in-licensing products and out-licensing own products and technologies to partners globally.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Polpharma Group develops, manufactures, and supplies generic and biosimilar medicines, active pharmaceutical ingredients (APIs), and contract development and manufacturing (CDMO) services. The company operates with vertical integration from API production through finished dosage forms, selling a portfolio of 4,000+ SKUs across prescription and OTC categories to customers in more than 40 countries through direct sales and partner networks.

Product overview

Polpharma Group is a leading regional pharmaceutical manufacturer in CEE and CIS markets, operating as a vertically integrated pharmaceutical company present along the entire pharmaceutical value chain. The company offers a portfolio of more than 4,000 SKUs across prescription medicines (generics including Hard-to-Make Generics and Novel Combinations) and consumer healthcare (OTC) products, with over 30 active pharmaceutical ingredients. Core business includes Polpharma CMO (contract manufacturing/CDMO services for finished dosage forms), Polpharma API (API production since 1951), and Farmaprojects (B2B licensing in Spain). The group operates through direct presence and strategic partnerships in over 40 countries, with key therapeutic strengths in pediatrics, cardiology, and ophthalmology. Annual production capacity reaches 5.2 billion tablets and 700 million capsules across eight competence centers in Poland, Kazakhstan, and Russia.

Differentiator

Problem solved

Functional benefit

Brands

• Polpharma CMO: Contract manufacturing organization providing finished dosage forms (FDF), licensing-out, and customized contract manufacturing services with full analytical support in GMP-compliant production plants
• Polpharma API

Products and services

• Prescription Medicines (Rx)
• Consumer Healthcare (CHC) / OTC Products
• Polpharma CMO (Contract Manufacturing)
• Polpharma API
• Farmaprojects
• Long Acting Injectables
• ECO Eye Drops
• Innovative Combos (Fixed Dose Combinations)
• Hard-to-Make Generics

Quantifiable outcome

• 400 million packages of medicines produced annually
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ApotexcoreStrategic or Co-development Partner · 1 January 2024Strategic partnership for co-marketing and co-development of products focused on diabetes care and cardiovascular disease. The collaboration aims to provide more patients in more markets with high quality and affordable products by sharing competencies and building on mutual strengths.
• NeuraxpharmcoreStrategic or Co-development Partner · 1 January 2014Strategic joint venture cooperation in the area of biotechnology established in 2014, combining Polpharma's manufacturing capabilities with Neuraxpharm's expertise in CNS therapies.
• Distribution and Out-licensing PartnerscoreChannel Partner/ Reseller/ DistributorNetwork of distribution and out-licensing partners operating in over 40 markets globally, enabling Polpharma products to reach patients across CEE, CIS, Central Asia, and SE Asia.
• Science and Research InstitutionsminorStrategic or Co-development PartnerCooperation with universities and research institutes both locally and abroad for drug development and innovation, crucial to agile action and creating higher value.
• Medicines for EuropecoreOthersIndustry association representing generic, biosimilar and value-added medicines industries across Europe. CEO Markus Sieger served as President (ad interim 2025) and Vice President (2022-2025) working on EU pharmaceutical legislation and supply security.
• IGBA (International Generic and Biosimilar medicines Association)coreOthersInternational network of generic medicines associations. CEO Markus Sieger joined the CEO Advisory Committee established to discuss strategic issues and position the industry on critical policy matters.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Teva Pharmaceutical Industries: The world's largest generic drug manufacturer with broad geographic reach, including heavy CEE/CIS presence and an extensive small-molecule generics plus biosimilars franchise — directly comparable to Polpharma's vertically integrated generics, API, and biosimilars model across multiple dosage forms.
• Sandoz Group: Novartis' generics and biosimilars spin-off, with a leading European generics footprint (small molecules, injectables, biosimilars) and active CDMO-style contract manufacturing. Most direct comparable to Polpharma on European generics + biosimilars + B2B CDMO business mix.
• Viatris: Global generics and biosimilars company formed from Mylan and Pfizer's Upjohn, serving both developed and emerging markets with off-patent medicines. Comparable to Polpharma on broad small-molecule generics portfolio, geographic diversification, and active CDMO/partner operations.
• Stada Arzneimittel: Private European-focused generic and consumer healthcare company owned by Bain/Cinven, with strong presence in Germany, CEE, and CIS markets. Closely comparable to Polpharma in target geographies, generics + OTC mix, and privately-held scale-up profile.
• Krka: Slovenian-headquartered generic pharmaceutical manufacturer with vertically integrated API-to-finished dosage form operations across CEE, CIS, and Western Europe. Highly comparable to Polpharma on geographic footprint, vertical integration, and hard-to-make generics strategy.
• Gedeon Richter: Hungarian pharmaceutical group with strong CEE/CIS heritage, generics and biosimilars portfolio, and listed equity status. Directly comparable to Polpharma's regional dominance, branded-generics mix, and biosimilars ambitions via Polpharma Biologics.
• Zentiva: European generics pure-play spun off from Sanofi and now owned by Advent International, with strong position in CEE (Czech heritage) and growing Western European presence. Directly comparable to Polpharma on European generic focus, CEE DNA, and private-equity ownership profile.
• Aurobindo Pharma: India-based vertically integrated generic pharmaceutical and API manufacturer with global distribution across 150+ countries. Comparable to Polpharma on generic formulations, large-scale API production, and CDMO/contract manufacturing services for global partners.
• Neuraxpharm: German specialty pharmaceutical company focused on CNS therapies and a Polpharma joint venture partner established in 2014. Comparable to Polpharma on European generics/specialty pharma, contract manufacturing collaboration, and CEE/CIS distribution footprint.

Emerging players

• Alvotech: Iceland-headquartered pure-play biosimilars developer with integrated manufacturing and commercial partnerships in Europe and US. Comparable to Polpharma Biologics on biosimilars focus, integrated development-to-manufacturing model, and CDMO-style partner licensing structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/polpharma-group

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polpharma Group